AR108295A1 - Composiciones y métodos para preparar anticuerpos basados en el uso de un locus mejorador de expresión - Google Patents
Composiciones y métodos para preparar anticuerpos basados en el uso de un locus mejorador de expresiónInfo
- Publication number
- AR108295A1 AR108295A1 ARP170101018A ARP170101018A AR108295A1 AR 108295 A1 AR108295 A1 AR 108295A1 AR P170101018 A ARP170101018 A AR P170101018A AR P170101018 A ARP170101018 A AR P170101018A AR 108295 A1 AR108295 A1 AR 108295A1
- Authority
- AR
- Argentina
- Prior art keywords
- methods
- locus
- compositions
- expression
- antibodies based
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 2
- 241000699802 Cricetulus griseus Species 0.000 abstract 2
- 210000003527 eukaryotic cell Anatomy 0.000 abstract 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 abstract 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 230000010354 integration Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/65—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression using markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/02—Cells for production
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Analytical Chemistry (AREA)
- Crystallography & Structural Chemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662325385P | 2016-04-20 | 2016-04-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR108295A1 true AR108295A1 (es) | 2018-08-08 |
Family
ID=58701850
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP170101018A AR108295A1 (es) | 2016-04-20 | 2017-04-20 | Composiciones y métodos para preparar anticuerpos basados en el uso de un locus mejorador de expresión |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11530277B2 (enExample) |
| EP (1) | EP3445780A1 (enExample) |
| JP (2) | JP7134868B2 (enExample) |
| KR (2) | KR20180134894A (enExample) |
| CN (2) | CN116004544A (enExample) |
| AR (1) | AR108295A1 (enExample) |
| AU (2) | AU2017253240B2 (enExample) |
| BR (1) | BR112018071285A2 (enExample) |
| CA (1) | CA3015371A1 (enExample) |
| EA (1) | EA201892137A1 (enExample) |
| IL (2) | IL309065A (enExample) |
| MX (2) | MX2018012866A (enExample) |
| SG (2) | SG10202010156XA (enExample) |
| TW (1) | TW201803981A (enExample) |
| WO (1) | WO2017184831A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL275462B1 (en) * | 2017-12-22 | 2025-09-01 | Genentech Inc | Targeted integration of nucleic acids |
| WO2020034097A1 (en) * | 2018-08-14 | 2020-02-20 | Wuxi Biologics (Shanghai) Co., Ltd. | Transcriptional regulatory element and its use in enhancing the expression of exogenous protein |
| KR102559149B1 (ko) * | 2018-10-26 | 2023-07-24 | 에프. 호프만-라 로슈 아게 | 재조합효소 매개 카세트 교환을 이용한 다중특이적 항체 스크리닝 방법 |
| TW202039852A (zh) * | 2018-12-21 | 2020-11-01 | 美商建南德克公司 | 核酸之靶向整合 |
| MX2021011837A (es) * | 2019-03-29 | 2021-10-22 | Hoffmann La Roche | Método para la generación de una célula que expresa el receptor neonatal de región de fragmento cristalizable (fcrn) mediante la integración dirigida de múltiples casetes de expresión en una organización definida. |
| IL286630B2 (en) | 2019-04-02 | 2025-05-01 | Chugai Pharmaceutical Co Ltd | Method for introducing a target-specific foreign gene |
| JP7410983B2 (ja) * | 2019-06-19 | 2024-01-10 | エフ． ホフマン－ラ ロシュ アーゲー | Ｃｒｅ ｍＲＮＡを使用した標的指向性組込みによるタンパク質発現細胞の作製のための方法 |
| EP3986926A1 (en) * | 2019-06-19 | 2022-04-27 | F. Hoffmann-La Roche AG | Method for the generation of a bivalent, bispecific antibody expressing cell by targeted integration of multiple expression cassettes in a defined organization |
| KR20220010549A (ko) | 2019-06-19 | 2022-01-25 | 에프. 호프만-라 로슈 아게 | 정의된 조직에서 다중 발현 카세트의 표적화된 통합에 의해 다가 이중특이성 항체 발현 세포를 생성하는 방법 |
| MX2021015540A (es) * | 2019-06-19 | 2022-02-10 | Hoffmann La Roche | Metodo para la generacion de una celula que expresa un anticuerpo trivalente mediante la integracion dirigida de multiples casetes de expresion en una organizacion definida. |
| MX2021015648A (es) * | 2019-06-19 | 2022-02-03 | Hoffmann La Roche | Metodo para la generacion de una celula que expresa un anticuerpo multiespecifico multivalente mediante integracion dirigida de multiples casetes de expresion en una organizacion definida. |
| WO2020264253A1 (en) * | 2019-06-26 | 2020-12-30 | Genentech, Inc. | Randomized configuration targeted integration of nucleic acids |
| EP4087925A2 (en) * | 2020-01-10 | 2022-11-16 | F. Hoffmann-La Roche AG | Method for the assembly of large nucleic acids from short fragments |
| EP4453227A1 (en) * | 2021-12-22 | 2024-10-30 | Genentech, Inc. | Multi-vector recombinase mediated cassette exchange |
| US20250122482A1 (en) | 2023-09-07 | 2025-04-17 | Regeneron Pharmaceuticals, Inc. | Production and purification of covalently surface modified adeno-associated virus |
| CN119955730A (zh) * | 2023-11-08 | 2025-05-09 | 深圳太力生物技术有限责任公司 | 一种细胞株及其制备方法与应用 |
| US20250163468A1 (en) | 2023-11-21 | 2025-05-22 | Regeneron Pharmaceuticals, Inc. | Covalently surface modified adeno-associated virus production by in vitro conjugation, and purification of covalently surface modified adeno-associated virus |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4656134A (en) | 1982-01-11 | 1987-04-07 | Board Of Trustees Of Leland Stanford Jr. University | Gene amplification in eukaryotic cells |
| US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
| US6800457B2 (en) | 1998-09-22 | 2004-10-05 | Bristol-Myers Squibb Company | Expression vectors containing hot spot for increased recombinant protein expression in transfected cells |
| CA2485939C (en) | 2002-05-29 | 2013-10-29 | Regeneron Pharmaceuticals, Inc. | Inducible eukaryotic expression system |
| AU2003298674A1 (en) | 2002-11-14 | 2004-06-15 | Genentech Inc | Intron fusion construct and method of using for selecting high-expressing production cell lines |
| US10011858B2 (en) | 2005-03-31 | 2018-07-03 | Chugai Seiyaku Kabushiki Kaisha | Methods for producing polypeptides by regulating polypeptide association |
| US8871912B2 (en) | 2006-03-24 | 2014-10-28 | Merck Patent Gmbh | Engineered heterodimeric protein domains |
| SI2041177T1 (sl) | 2006-06-02 | 2012-03-30 | Regeneron Pharma | Visoko afinitetna protitelesa za humani IL receptor |
| WO2008079943A2 (en) | 2006-12-21 | 2008-07-03 | Smithkline Beecham Corporation | Novel methods |
| WO2008089396A1 (en) | 2007-01-19 | 2008-07-24 | Invitrogen Corporation | Compositions and methods for genetic manipulation and monitoring of cell lines |
| AU2008234248C1 (en) | 2007-03-29 | 2015-01-22 | Genmab A/S | Bispecific antibodies and methods for production thereof |
| ES2522615T3 (es) * | 2007-06-04 | 2014-11-17 | Regeneron Pharmaceuticals, Inc. | Regiones de expresión y estabilidad potenciadas |
| SI2235064T1 (sl) | 2008-01-07 | 2016-04-29 | Amgen Inc. | Metoda za izdelavo heterodimernih molekul - protitelesa fc z uporabo elektrostatičnih usmerjevalnih učinkov |
| SG176251A1 (en) | 2009-06-02 | 2011-12-29 | Regeneron Pharma | Fucosylation-deficient cells |
| RU2522002C2 (ru) | 2009-06-26 | 2014-07-10 | Ридженерон Фармасьютикалз, Инк. | Легковыделяемые биспецифические антитела с природным иммуноглобулиновым форматом |
| US20120302737A1 (en) | 2009-09-16 | 2012-11-29 | Genentech, Inc. | Coiled coil and/or tether containing protein complexes and uses thereof |
| EA201201435A1 (ru) | 2010-04-20 | 2013-04-30 | Генмаб А/С | ГЕТЕРОДИМЕРНЫЕ АНТИТЕЛО-Fc-СОДЕРЖАЩИЕ БЕЛКИ И СПОСОБЫ ИХ ПОЛУЧЕНИЯ |
| MX338953B (es) | 2010-08-16 | 2016-05-06 | Novimmune Sa | Metodos para la generacion de anticuerpos multiespecificos y multivalentes. |
| DK2739740T3 (da) | 2011-08-05 | 2019-12-09 | Regeneron Pharma | Universelle, humaniserede letkæde-mus |
| TW201823460A (zh) | 2012-05-29 | 2018-07-01 | 美商再生元醫藥公司 | 生產細胞株增強子 |
| EP2711428A1 (en) | 2012-09-21 | 2014-03-26 | Lonza Biologics plc. | Site-specific integration |
| JOP20200236A1 (ar) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| TWI864338B (zh) | 2012-11-14 | 2024-12-01 | 美商再生元醫藥公司 | 重組細胞表面捕捉蛋白質 |
| TWI682941B (zh) * | 2013-02-01 | 2020-01-21 | 美商再生元醫藥公司 | 含嵌合恆定區之抗體 |
| US20140308285A1 (en) | 2013-03-15 | 2014-10-16 | Amgen Inc. | Heterodimeric bispecific antibodies |
| TWI728373B (zh) | 2013-12-23 | 2021-05-21 | 美商建南德克公司 | 抗體及使用方法 |
| TWI701042B (zh) | 2014-03-19 | 2020-08-11 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
| CN107109434A (zh) | 2014-10-23 | 2017-08-29 | 瑞泽恩制药公司 | 新颖cho整合位点和其用途 |
| RS62859B1 (sr) | 2015-09-23 | 2022-02-28 | Regeneron Pharma | Optimizovana anti-cd3 bispecifična antitela i njihove upotrebe |
-
2017
- 2017-04-20 SG SG10202010156XA patent/SG10202010156XA/en unknown
- 2017-04-20 AR ARP170101018A patent/AR108295A1/es unknown
- 2017-04-20 MX MX2018012866A patent/MX2018012866A/es unknown
- 2017-04-20 SG SG11201807881VA patent/SG11201807881VA/en unknown
- 2017-04-20 US US16/095,067 patent/US11530277B2/en active Active
- 2017-04-20 AU AU2017253240A patent/AU2017253240B2/en active Active
- 2017-04-20 CA CA3015371A patent/CA3015371A1/en active Pending
- 2017-04-20 EA EA201892137A patent/EA201892137A1/ru unknown
- 2017-04-20 IL IL309065A patent/IL309065A/en unknown
- 2017-04-20 TW TW106113300A patent/TW201803981A/zh unknown
- 2017-04-20 KR KR1020187029371A patent/KR20180134894A/ko not_active Ceased
- 2017-04-20 BR BR112018071285A patent/BR112018071285A2/pt not_active Application Discontinuation
- 2017-04-20 WO PCT/US2017/028552 patent/WO2017184831A1/en not_active Ceased
- 2017-04-20 EP EP17723182.6A patent/EP3445780A1/en active Pending
- 2017-04-20 IL IL262268A patent/IL262268B2/en unknown
- 2017-04-20 KR KR1020217035334A patent/KR102474757B1/ko active Active
- 2017-04-20 CN CN202211344339.4A patent/CN116004544A/zh active Pending
- 2017-04-20 JP JP2018552822A patent/JP7134868B2/ja active Active
- 2017-04-20 CN CN201780024560.2A patent/CN109071633B/zh active Active
-
2018
- 2018-10-19 MX MX2024014381A patent/MX2024014381A/es unknown
-
2022
- 2022-08-31 JP JP2022137796A patent/JP7546015B2/ja active Active
- 2022-11-10 US US18/054,350 patent/US20230322956A1/en active Pending
-
2024
- 2024-09-26 AU AU2024220126A patent/AU2024220126A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20230322956A1 (en) | 2023-10-12 |
| IL262268B1 (en) | 2024-01-01 |
| KR20210135340A (ko) | 2021-11-12 |
| US20190263937A1 (en) | 2019-08-29 |
| SG10202010156XA (en) | 2020-11-27 |
| JP7134868B2 (ja) | 2022-09-12 |
| KR102474757B1 (ko) | 2022-12-07 |
| MX2018012866A (es) | 2019-03-11 |
| CN109071633A (zh) | 2018-12-21 |
| CN109071633B (zh) | 2022-11-18 |
| IL309065A (en) | 2024-02-01 |
| EP3445780A1 (en) | 2019-02-27 |
| BR112018071285A2 (pt) | 2019-02-12 |
| KR20180134894A (ko) | 2018-12-19 |
| JP2022164824A (ja) | 2022-10-27 |
| IL262268A (en) | 2018-11-29 |
| JP2024164196A (ja) | 2024-11-26 |
| CN116004544A (zh) | 2023-04-25 |
| AU2017253240B2 (en) | 2024-07-04 |
| JP7546015B2 (ja) | 2024-09-05 |
| MX2024014381A (es) | 2024-12-06 |
| SG11201807881VA (en) | 2018-10-30 |
| JP2019514358A (ja) | 2019-06-06 |
| AU2024220126A1 (en) | 2024-10-17 |
| EA201892137A1 (ru) | 2019-03-29 |
| IL262268B2 (en) | 2024-05-01 |
| TW201803981A (zh) | 2018-02-01 |
| US11530277B2 (en) | 2022-12-20 |
| AU2017253240A1 (en) | 2018-09-20 |
| CA3015371A1 (en) | 2017-10-26 |
| WO2017184831A1 (en) | 2017-10-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR108295A1 (es) | Composiciones y métodos para preparar anticuerpos basados en el uso de un locus mejorador de expresión | |
| MX2018012868A (es) | Composiciones y metodos para generar anticuerpos basado en el uso de loci potenciadores de expresion. | |
| CL2018002081A1 (es) | Inhibidores de la proteína quinasa 1 que interactua con el receptor | |
| CL2015002654A1 (es) | Polipéptidos de il-22 y proteínas de fusión de il-22 fc y métodos de uso | |
| ECSP18094857A (es) | Agonista del receptor de glucocorticoides e inmunoconjugados del mismo | |
| ECSP17063327A (es) | Receptores de antígeno quiméricos antidll3 y métodos de uso | |
| CO2020009644A2 (es) | Esteroides y conjugados de anticuerpos de los mismos | |
| MX2024001394A (es) | Anticuerpos anti-bcma unicamente de cadena pesada. | |
| CO2019003154A2 (es) | Anticuerpos anti-pd-1 y sus usos | |
| AR095437A1 (es) | Proteínas de fusión comprendiendo porciones pdgf y vegf de unión y métodos para su uso | |
| PE20181005A1 (es) | Anticuerpos biespecificos contra el a- beta humano y el receptor de transferrina humano y metodos de uso | |
| MX394528B (es) | Esteroides y conjugados de proteinas de los mismos. | |
| CR20220186A (es) | ANTICUERPOS ANTI-TIGIT Y MÉTODOS DE USO (divisional 2018-0225) | |
| MX2020004801A (es) | Polipeptidos de fusion biespecificos y sus metodos de uso. | |
| CR20180605A (es) | Anticuerpos anti-cd40 y sus usos | |
| MX2016010128A (es) | Acoplador trifuncional de antigeno de celulas t y metodos y usos del mismo. | |
| BR112015030946A8 (pt) | composição compreendendo uma célula ß pancreática não-nativa, método de diferenciação de células progenitoras em células ß pancreáticas in vitro e uso de uma célula ß pancreática não-nativa | |
| MX374853B (es) | Anticuerpos anti-proteína que contiene domino de inmunologlubina relacionado con el receptor de poliovirus (pvrig) y metodos de uso. | |
| CO2017002159A2 (es) | Derivados de heterociclilo opcionalmente condensados de pirimidina útiles para el tratamiento de enfermedades inflamatorias, metabólicas, oncológicas y autoinmunitarias | |
| MX2019000641A (es) | Composiciones de mucina1-receptor de antigeno quimerico y metodos para su uso. | |
| MX2018003822A (es) | Anticuerpos biespecificos contra el cd20 humano y el receptor de transferrina humano y metodos de uso. | |
| MX2017008817A (es) | Composiciones y metodos para la glicosilacion de proteinas. | |
| EA201791275A1 (ru) | Способы получения ctp-модифицированных полипептидов длительного действия | |
| CO2020003020A2 (es) | Herbicidas de carboxilato de piridina y pirimidina y métodos para su uso | |
| AR095348A1 (es) | Medios de cultivo celular y métodos de producción de anticuerpos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |